Human chorionic gonadotropin (hCG)
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Chorionic gonadotropin - gonadotropic hormone. It is produced by human placenta and excreted into the urine, from where it can be extracted and purified. Stimulates the production of progesterone by the corpus luteum and supports the development of the placenta. It has gonadotropic action, mainly luteinizing.
In women, the drug causes ovulation and stimulates the synthesis of estrogen and progesterone. In men, it stimulates spermatogenesis and the production of sex steroids.
After the / m injection is well absorbed. T1 / 2 is 8 h.
It is believed that before excretion with urine, chorionic gonadotropin is modified in the body, since its T1 / 2, measured by the immunological method, significantly exceeds this indicator, determined by biological activity.
For women: induction of ovulation after stimulation of follicle growth; maintaining the function of the corpus luteum of the ovary in patients with luteal phase insufficiency.
For boys and men: cryptorchidism (ectopia, testicular retention in the abdominal cavity or in the inguinal canal); delayed puberty; hypogonadotropic hypogonadism (in combination with human menopausal gonadotropin preparations); during the differential diagnostic test for anorchism and cryptorchidism in boys; when conducting a functional Leydig test to assess testicular function in hypogonadotropic hypogonadism before beginning a long-term stimulatory treatment
1 bottle contains:
Active substance: chorionic gonadotropin 1000 ED.
Human chorionic gonadotropin (hCG) is marketed under different brands and generic names, and comes in different dosage forms:
|Brand name||Manufacturer||Country||Dosage form|
|Chorionic gonadotropin||Moscow Endocrine Plant||Russia||vials|
No customer reviews for the moment.
Dosage and Administration
Chorionic gonadotropin administered intramuscularly. The dose is individualized depending on the nature, severity of the disease and the age of the patient and ranges from 500 to 3000 units per day.
For men, the drug is administered 2-3 times a week in courses of 4 weeks at intervals of 4-6 weeks. Conduct 3-6 courses for 6-12 months. Prolonged continuous use of the drug is not recommended because of the risk of antibody formation and suppression of the pituitary gonadotropic function.
With anovulatory cycles with a high level of estrogen in women, which indicates the normal maturation of the follicles, the drug is administered from the 10th to the 12th day of the cycle, 3000 IU 2-3 times with an interval of 2-3 days or 1500 IU 6-7 times day.
On the part of the endocrine system in women:may develop ovarian hyperstimulation syndrome, accompanied by the development of ovarian cysts with the risk of rupture, ascites, hydrothorax and the risk of thromboembolism.
On the part of the endocrine system in boys and men: temporary reversible enlargement of the mammary glands, prostate gland, water and electrolyte retention, and acne are possible; in boys, behavioral changes similar to those observed during the first phase of puberty, which take place after the end of treatment, are possible.
- Tumors of various localization, dependent on sex hormones;
- organically induced cryptorchidism (inguinal hernia, consequences of surgical interventions in the inguinal region, abnormal position of the testicles) in boys and men;
- hypersensitivity to human chorionic gonadotropin.
Chorionic gonadotropin is used in combination with menopausal gonadotropin in the treatment of infertility.
Solutions are prepared immediately before use in an isotonic solution of sodium chloride. It is necessary to take into account the probability of false-positive results of immunological analysis for the content of endogenous chronic hepatitis and the possibility of increasing the concentration of 17-hydroxycorticosteroids and 17-ketosteroids in the urine.
- Active ingredient: Human chorionic gonadotropin (hCG)
- Dosage form: Injections
- Mass Spectrometric Characterization of the β-Subunit of Human Chorionic Gonadotropin
- Localization of human chorionic gonadotropin and placental lactogen by immunogold labeling for electron microscopy: Technique and limitations
- Human chorionic gonadotropin-beta subunit gene expression in cultured human fetal and cancer cells of different types and origins
- Metastatic phenotype correlates with high expression of membrane-associated complete β-human chorionic gonadotropin in vivo
- Demonstration of dose dependent cytotoxic activity in cancer cells by specific human chorionic gonadotropin monoclonal antibodies
- Immunohistochemical study of the expression of human chorionic gonadotropin-β in oral squamous cell carcinoma
- Detection of β-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma
- Expression of α and β genes of human chorionic gonadotropin in lung cancer
- Human chorionic gonadotropin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: Possible role of up-regulation of insulin-like growth factor-1 by hCG
- SECOND-TRIMESTER MATERNAL SERUM ALPHA-FETOPROTEIN, HUMAN CHORIONIC GONADOTROPIN, AND UNCONJUGATED OESTRIOL AFTER EARLY TRANSVAGINAL MULTIFETAL PREGNANCY REDUCTION
- MATERNAL SERUM TESTING FOR ALPHA-FETOPROTEIN AND HUMAN CHORIONIC GONADOTROPIN IN HIGH-RISK PREGNANCIES
- LETTER TO THE EDITOR. Re: Second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol after early transvaginal mutlifetal pregancy reduction
- Relationship between maternal serum levels of alpha-fetoprotein and human chorionic gonadotropin in the early second trimester
- Maternal serum alpha-fetoprotein and human chorionic gonadotropin in pregnant women with acute parvovirus B19 infection with and without fetal complications
- Preliminary evidence for associations between second-trimester human chorionic gonadotropin and unconjugated oestriol levels with pregnancy outcome in Down syndrome pregnancies
- Inhibition of rat mammary tumorigenesis by human chorionic gonadotropin associated with increased expression of inhibin
- Assays of antibodies to a C-terminal peptide or the entire β-subunit of human chorionic gonadotropin
- Effect of desialylated human chorionic gonadotropin (hCG) on the bioactivity of rat Leydig cells
- Altered newborn gender distribution in patients with low mid-trimester maternal serum human chorionic gonadotropin (MShCG)
- Discordance of human chorionic gonadotropin and alpha-fetoprotein in testicular teratocarcinomas
- Ectopic production of human chorionic gonadotropin in ugandan patients with hepatocellular carcinoma
- The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors
- Criteria of complete remission from trophoblastic neoplasia with the use of human chorionic gonadotropin (hCG) excretion pattern as a parameter